Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma - Concepedia

Concepedia

Publication | Open Access

Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma

DOI Full Paper Access

76

Citations

19

References

2007

Year

Malcolm S. Mitchell, Judith Abrams, John A. Thompson, Mohammed Kashani–Sabet, Ronald C. DeConti, Wen-Jen Hwu, Michael B. Atkins, Eric D. Whitman, Marc S. Ernstoff, Frank G. Haluska,

Journal of Clinical Oncology

Abstract

OS and RFS achieved by active specific immunotherapy and low-dose IFN-alpha-2b were indistinguishable from those achieved by high-dose IFN-alpha-2b. Long RFS and OS times were observed in both treatment arms.

References

	Year	Citations

Page 1